Northern Territory Medical Program, Flinders University, Royal Darwin Hospital, Tiwi, NT, Australia.
Northern Territory Medical Program, Flinders University, Royal Darwin Hospital, Tiwi, NT, Australia; Department of Nephrology, Division of Medicine, Royal Darwin Hospital, Tiwi, NT, Australia; Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
Heart Lung Circ. 2019 Jul;28(7):1042-1049. doi: 10.1016/j.hlc.2018.06.1038. Epub 2018 Jun 19.
Heart failure (HF) is associated with significant morbidity and mortality and recurrent hospitalisations, particularly in the Indigenous Australians of the Northern Territory. In remote Northern Australia, the epidemiology is less clear but anecdotal evidence suggests it may be worse. In addition, some anecdotal evidence suggests that prognostic pharmacological therapy could also be underutilised. Minimal HF data exists in the remote and Indigenous settings, making this study unique.
A retrospective cohort review of pharmacological management of 99 patients from 1 January 2014 to 31 December 2014 was performed.
Ninety-nine (99) patients were identified. 59.6% were non-Indigenous vs 40.4% Indigenous. The majority was male (69.7%). Indigenous patients were younger; median age was 51.4 (43.4-60.6) vs 70.5 (62.2-77.0), p<0.001. Major causes of HF were coronary artery disease (61%) and dilated cardiomyopathy (27%). Associated comorbidities included hypertension (52%), dyslipidaemia (38%), diabetes mellitus (40%) and atrial fibrillation (25%). The use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and β-blocker was 68% and 87%, respectively. Forty-one (41) patients not on an ACEI/ARB and/or β-blocker were identified. Seventeen (17) of those patients (42%) did not receive an ACEI/ARB because of renal failure. Four (4) patients (10%) did not take a β-blocker due to hypotension. Fourteen (14) patients (34%) were not prescribed an ACEI/ARB and/or β-blocker had no identifiable contraindications.
Indigenous patients are over-represented at a younger age demonstrating the alarming rate of disease burden in NT's young Indigenous population. Generally, ACEI/ARBs were underutilised compared to β-blockers with renal impairment being the primary contraindication. There is a need to develop processes to further improve the use of heart failure medications and setting up a HF database could be the first step in progress.
心力衰竭(HF)与较高的发病率和死亡率以及反复住院有关,尤其是在北领地的澳大利亚原住民中。在澳大利亚北部偏远地区,其流行病学情况不太清楚,但一些传闻证据表明,情况可能更糟。此外,一些传闻证据表明,预后药物治疗的应用也可能不足。在偏远和原住民地区,HF 数据很少,因此这项研究具有独特性。
对 2014 年 1 月 1 日至 2014 年 12 月 31 日期间 99 例患者的药物治疗进行回顾性队列研究。
共确定了 99 例患者。59.6%是非原住民,40.4%是原住民。大多数为男性(69.7%)。原住民患者年龄较小;中位年龄为 51.4(43.4-60.6)岁比 70.5(62.2-77.0)岁,p<0.001。HF 的主要病因是冠状动脉疾病(61%)和扩张型心肌病(27%)。并存的合并症包括高血压(52%)、血脂异常(38%)、糖尿病(40%)和心房颤动(25%)。血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEI/ARB)和β受体阻滞剂的使用率分别为 68%和 87%。确定了 41 例未使用 ACEI/ARB 和/或β受体阻滞剂的患者。其中 17 例(42%)由于肾功能衰竭未使用 ACEI/ARB。由于低血压,有 4 例(10%)患者未服用β受体阻滞剂。由于无明确禁忌证,14 例(34%)未开具 ACEI/ARB 和/或β受体阻滞剂的患者。
原住民患者在较年轻的年龄组中占比过高,表明 NT 年轻原住民人群中疾病负担的惊人速度。一般来说,与β受体阻滞剂相比,ACEI/ARB 的应用不足,而肾功能不全是主要的禁忌证。需要制定进一步改善心力衰竭药物使用的流程,建立心力衰竭数据库可能是取得进展的第一步。